ClinicalTrials.gg
CompletedNCT05513937BotticelliUpdated Feb 4, 2025Results posted

Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy

A Phase 4 interventional study of Nebivolol and Amlodipine in Hypertension, sponsored by Menarini International Operations Luxembourg SA. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Menarini International Operations Luxembourg SA (part of Menarini Group) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2022, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
301
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing nebivolol in Hypertension — none open to participants now, 1 under way, none of them phase 3. Nebivolol · Hypertension.

Enrollment
12th of 58
301 · median 70
Started
2022
the only one that year
Phase 4
29 of 58
none open now
Registered
56th of 58
by date
Lead sponsor
3 of 58
Menarini International Operations Luxembourg SA

Among the 58 studies testing nebivolol in Hypertension, this one is the 12th largest by enrollment, is the only one that started in 2022, is one of 29 in phase 4, and was the 56th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 58 studies testing nebivolol in Hypertension is open now. The open studies under Hypertension, anywhere →

About nebivolol

Nebivolol: first FDA approval 2007 (BYSTOLIC). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 58 studies testing nebivolol in Hypertension as a file.
02

Study summary

Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Nebivolol 5 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment inpatients with uncontrolled BP previously treated with Nebivolol (NEB) or Amlodipine (5 mg) monotherapies for at least 4 weeks.

Read the detailed description

Approximately 290 patients are planned to be screened to ensure at least 216 patients complete the run-in period and start with the assessment period.

Grade 1 - 2 hypertensive patients [BP ranging from ≥140 to ≤179 mmHg for Systolic Blood Pressure (SBP) and from ≥90 to ≤109 mmHg for Diastolic Blood Pressure (DBP)] on treatment with any Beta Blocker (BB) or Calcium Channel Blocker (CCB), including NEB (only 5 mg dosage allowed) or AML (only 5 mg dosage allowed) for at least one month prior to Visit 1 will be screened for eligibility.

Allowed CCBs at screening includes Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine. Patients treated with Amlodipine or Nebivolol in dosages higher than 5 mg/daily will not be eligible.

On the same day of the Screening visit, the eligible patients will enter into a run-in period of 4 weeks after screening, during which:

  • Patients receiving NEB 5 mg or AML 5 mg will continue the same therapy for 4 weeks.
  • Patients on any other BBs or CCBs will be switched to NEB 5 mg or AML 5 mg. Patients entering this phase in therapy with NEB 5 mg or AML 5 mg should be in a 1:1 ratio.

After 4 weeks (±2 days) of run-in period of monotherapy, the BP will be further assessed (Visit 2). Patients with uncontrolled BP levels (sitting SBP/DBP ≥130/80 mmHg) at Visit 2, with the treatment adherence (ranging between 80% to 120%) and who did tolerate the treatment will enter into the assessment period and will be assigned to the extemporaneous combination of NEB 5 mg and AML 5 mg. Patients with controlled BP levels (sitting SBP/DBP \<130/80 mmHg) and/or who do not tolerate the treatment or have an adherence range below 80% or above 120%, will be withdrawn from the study.

After 4 weeks ±2 days in the assessment period, patients BP will be further evaluated at Visit 3: patients with controlled BP levels (sitting SBP/DBP \<130/80 mmHg) will continue the same extemporaneous combination, while patients with uncontrolled BP levels will be uptitrated from extemporaneous combination NEB/AML 5/5 mg to extemporaneous combination of NEB/AML 5/10 mg for further 4 weeks.

At the end of the assessment period (8 weeks ±4 days), the patients will attend an End of Treatment Visit 4.

To correctly evaluate the additional effect of the combination therapy, the number of patients with uncontrolled BP on NEB or AML monotherapy needs to be balanced at Visit 2. In order to maintain a 1:1 ratio during the assessment period, a cap of 110 patients for each treatment arm (ie. NEB and AML) will be included at Visit 2 in order to maintain a balanced number of uncontrolled patients entering the assessment period for each drug. The evaluation will be done every 50 patients. If the rate of entrance in the assessment period for one of the 2 tested drugs will deviate more than 5%, a corrective measure will be initiated.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with Grade 1 - 2 hypertension with mean sitting SBP ≥140 mmHg and ≤179 mmHg and/or mean sitting DBP ≥90 mmHg and ≤109 mmHg at screening (in accordance with the 2018 European Society of Cardiology / European Society of Hypertension guidelines definition), ≥18 and \<65 years of age, on monotherapy treatment either with BBs or CCBs for at least 4 weeks before Visit 1 (screening).
  2. Patients are able to understand and have freely given written at Screening Visit.
  3. Patients who are able to comply with all study procedures and who are available for the duration of the study.
  4. Ability to take oral medication and willing to adhere to the drug regimen.
  5. Female patients are eligible to participate if not pregnant, or not breastfeeding and if they refrain from donating or storing eggs. For females of : use of highly effective (eg. method of birth control throughout the study period and for 4 weeks after study completion defined as a method which results in a failure rate of \<1% per year) such as:

    • Combined hormonal contraception (estrogen- and progestogen-containing) associated with inhibition of ovulation (oral, intravaginal, and transdermal).
    • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, and implantable).
    • Intrauterine device.
    • Intrauterine hormone-releasing system.
    • Bilateral tubal occlusion.
    • Vasectomized partner (procedure conducted at least 2 months before the screening), (provided the partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success).
  6. A male patient must agree to use contraception during the whole study period and for at least 1 week after the last dose of study treatment and refrain from donating sperms during this period.

Exclusion criteria

Exclusion Criteria:

  1. Patients with significant history of to nebivolol, amlodipine, other BBs or other dihydropyridines, or any related products (including of the formulations) as outlined in the relevant Investigators Brochures, summary of product characteristics12,13 or local package inserts for NEB and AML.
  2. Patients with serious disorders (in the opinion of the Investigator) which may limit the ability to evaluate the efficacy or safety of the tested medications, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, hematological, or oncological, neurological, and psychiatric diseases. The same applies for and/or neutropenic patients.
  3. Patients having a history of the following conditions within the last 6 months: myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, bypass surgery, heart failure, hypertensive encephalopathy, valve replacement (transcatheter aortic valve implantation, mitraclip), cerebrovascular accident (stroke), or .
  4. Patients with condition of hypotension with SBP \<90 mmHg and/or DBP \<60 mmHg.
  5. Acute heart failure, cardiogenic shock, or episodes of heart failure decompensation requiring intravenous inotropic therapy.
  6. Patients with secondary hypertension of any etiology including renal diseases, pheochromocytoma, Cushing's syndrome, hyperaldosteronism, renovascular disease, and thyroid disorders.
  7. Patients with a narrowing of the aortic or bicuspid valve, an obstruction of cardiac outflow (obstructive, hypertrophic cardiomyopathy), obstruction of the outflow tract of the left ventricle (eg. high grade aortic stenosis) or symptomatic coronary disease.
  8. Patients with severe renal impairment or renal transplant.
  9. Patients with hepatic impairment.
  10. Patients with sick sinus syndrome, including sino-atrial block.
  11. Patients with second- or third-degree heart block (without a pacemaker).
  12. Patients with history of bronchospasm and bronchial asthma.
  13. Patients with untreated pheochromocytoma.
  14. Patients with bradycardia (heart rate \<60 bpm; \<50 bpm in patients already on BBs treatment).
  15. Patient with metabolic acidosis.
  16. Patients with severe peripheral circulatory disturbances.
  17. Participation in another interventional study within the last 4 weeks before Screening Visit (Visit 1).
  18. Patients with diseases that, in the opinion of the Investigator, prevent a careful adherence to the protocol.
  19. Patients using and not suitable for withdrawing the prohibited medications prior to the administration of study treatment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
301 participants (actual)

Study arms

  • Active comparator
    Nebivolol 5 mg

    MONOTHERAPY PHASE 4 weeks (Run-in from -4 week to week 0): patients will be treated with Nebivolol 5mg COMBINATION THERAPY PHASE 8 weeks (from week 0 to week 8): uncontrolled patients during Monotherapy Phase will be treated with the extemporaneous combination of Nebivolol 5mg and Amlodipine 5mg for 4 weeks (from week 0 to week 4). Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks (from week 4 to week 8) while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.

    Drug: Nebivolol · Drug: Amlodipine

  • Active comparator
    Amlodipine 5/10 mg

    MONOTHERAPY PHASE 4 weeks (Run-in from -4 week to week 0): patients will be treated with Amlodipine 5mg COMBINATION THERAPY PHASE 8 weeks (from week 0 to week 8): uncontrolled patients during Monotherapy Phase will be treated with the extemporaneous combination of Nebivolol 5mg and Amlodipine 5mg for 4 weeks (from week 0 to week 4). Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks (from week 4 to week 8) while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.

    Drug: Nebivolol · Drug: Amlodipine

Interventions

  • Tablets administered orally once daily according instructions provided by Principal Investigator.

  • Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)

    To assess the antihypertensive efficacy of the extemporaneous combination of Nebivolol (NEB) 5 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Nebivolol or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.

    Time frame: From Visit 2 (week 0) to Visit 4 (week 8) for a total of 8 weeks

07

Results

Posted Feb 4, 2025

Participant flow

Run in (-4 Week to 0) Monotherapy Phase
Participant flow — Run in (-4 Week to 0) Monotherapy Phase
MilestoneRun-In Nebivolol 5mgRun-In Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 10mg
Started14315800
Completed13915200
Not completed4600
Withdrew: Newly developed or not previously recognized exclusion criteria0100
Withdrew: Protocol violation2500
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject1000
Combination Therapy (0 to 4 Weeks)
Participant flow — Combination Therapy (0 to 4 Weeks)
MilestoneRun-In Nebivolol 5mgRun-In Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 10mg
Started002790
Completed002790
Not completed0000
Combination Therapy (4 to 8 Weeks)
Participant flow — Combination Therapy (4 to 8 Weeks)
MilestoneRun-In Nebivolol 5mgRun-In Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 10mg
Started0018594
Completed0018294
Not completed0030
Withdrew: Adverse event0020
Withdrew: Protocol violation0010

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)

To assess the antihypertensive efficacy of the extemporaneous combination of Nebivolol (NEB) 5 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Nebivolol or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.

Time frame:
From Visit 2 (week 0) to Visit 4 (week 8) for a total of 8 weeks
Reported as:
Mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)
mmHgCombination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg
Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)-15.2 ± 8.32
Statistical analysis
  • Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg · Wilcoxon signed rank test · p = <0.001 · Mean difference pre vs post: -15.2

Adverse events

Collected over From Informed Consent signature at screening visit (Visit 1) occurring 4 week previous than Baseline assessment (Week 0 - Visit 2) to last visit at Week 8 (Visit 4) for an average of 12 weeks. Furthermore patients having any ongoing Adverse Event/Serious Adverse Event at the end of the treatment (Week 8 - Visit 4), will be followed for further 2 weeks via a phone call to check about the status of the Adverse Events/Serious Adverse Events, extending the time frame to a total of 14 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nebivolo 5 mg MONOTHERAPY PERIOD0/143 (0%)0/143 (0%)4/143 (2.8%)
Amlodipine 5 mg MONOTHERAPY PERIOD0/158 (0%)0/158 (0%)2/158 (1.3%)
Nebivolo 5mg/Amlodipine 5 mg COMBINATION THERAPY PERIOD0/279 (0%)0/279 (0%)35/279 (12.5%)
Nebivolo 5mg/Amlodipine 10mg COMBINATION THERAPY PERIOD0/94 (0%)0/94 (0%)9/94 (9.6%)
Most frequent other events
Showing 10 of 38
Most frequent other events
EventNebivolo 5 mg MONOTHERAPY PERIODAmlodipine 5 mg MONOTHERAPY PERIODNebivolo 5mg/Amlodipine 5 mg COMBINATION THERAPY PERIODNebivolo 5mg/Amlodipine 10mg COMBINATION THERAPY PERIOD
Hepatic enzyme increasedInvestigations0/1430/1580/2793/94
Back painMusculoskeletal and connective tissue disorders0/1430/1583/2793/94
HeadacheNervous system disorders0/1431/1587/2790/94
ArthralgiaMusculoskeletal and connective tissue disorders0/1430/1586/2790/94
VertigoEar and labyrinth disorders1/1431/1583/2790/94
ToothacheGastrointestinal disorders0/1430/1583/2790/94
Feeling HotGeneral disorders0/1430/1581/2791/94
TachycardiaCardiac disorders0/1430/1580/2791/94
DiarrhoeaGastrointestinal disorders0/1430/1582/2791/94
ErythemaSkin and subcutaneous tissue disorders0/1430/1581/2791/94

Baseline characteristics

Age, Continuous
Age, Continuous(years)Combination Therapy Nebivolol 5mg/ Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 10mgTotal
Mean51.5 ± 8.1453.4 ± 8.0252.2 ± 8.13
Sex: Female, Male
Sex: Female, Male(Participants)Combination Therapy Nebivolol 5mg/ Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 10mgTotal
Female9945144
Male8649135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Combination Therapy Nebivolol 5mg/ Amlodipine 5mgCombination Therapy Nebivolol 5mg/ Amlodipine 10mgTotal
Hispanic or Latino000
Not Hispanic or Latino18594279
Unknown or Not Reported000
08

Study locations

1 site
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Nov 2022, 6 months.

Results were first posted in Feb 2025, 2 years 2 months after primary completion.

Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 6 months is below that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 24, 2022
StartActual
May 12, 2022
Primary completionActual
Nov 15, 2022
CompletionActual
Nov 15, 2022
Results first posted
Feb 4, 2025
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05513937
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
May 12, 2022
Primary completion
Nov 15, 2022
Completion
Nov 15, 2022
Results posted
Feb 4, 2025
Last update
Feb 4, 2025

Study contacts

Massimo Volpe
principal investigator · University "Sapienza" Rome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nebivolol · Amlodipine

Start the discussion